710 related articles for article (PubMed ID: 31552054)
1. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
2. X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
O'Riordan CE; Purvis GSD; Collotta D; Krieg N; Wissuwa B; Sheikh MH; Ferreira Alves G; Mohammad S; Callender LA; Coldewey SM; Collino M; Greaves DR; Thiemermann C
Front Immunol; 2020; 11():581758. PubMed ID: 33162995
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
4. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
[TBL] [Abstract][Full Text] [Related]
5. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Kriegsmann K; Kriegsmann M; Witzens-Harig M
Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
[TBL] [Abstract][Full Text] [Related]
6. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB.
Al Zoubi S; Chen J; Murphy C; Martin L; Chiazza F; Collotta D; Yaqoob MM; Collino M; Thiemermann C
Front Immunol; 2018; 9():2996. PubMed ID: 30619349
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Ghosh S; Mohammed Z; Singh I
J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
[TBL] [Abstract][Full Text] [Related]
8. CD38-mediated Inhibition of Bruton's Tyrosine Kinase in Macrophages Prevents Endotoxemic Lung Injury.
Farahany J; Tsukasaki Y; Mukhopadhyay A; Mittal M; Nepal S; Tiruppathi C; Malik AB
Am J Respir Cell Mol Biol; 2022 Feb; 66(2):183-195. PubMed ID: 34706199
[TBL] [Abstract][Full Text] [Related]
9. Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Pikatan NW; Liu YL; Bamodu OA; Hsiao M; Hsu WM; Haryana SM; Sutaryo ; Chao TY; Yeh CT
Cell Oncol (Dordr); 2020 Dec; 43(6):1067-1084. PubMed ID: 32705581
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bruton's TK regulates macrophage NF-κB and NLRP3 inflammasome activation in metabolic inflammation.
Purvis GSD; Collino M; Aranda-Tavio H; Chiazza F; O'Riordan CE; Zeboudj L; Mohammad S; Collotta D; Verta R; Guisot NES; Bunyard P; Yaqoob MM; Greaves DR; Thiemermann C
Br J Pharmacol; 2020 Oct; 177(19):4416-4432. PubMed ID: 32608058
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.
Patel NM; Oliveira FRMB; Ramos HP; Aimaretti E; Alves GF; Coldewey SM; Collino M; Sordi R; Thiemermann C
Ann Surg; 2023 Mar; 277(3):e624-e633. PubMed ID: 35129479
[TBL] [Abstract][Full Text] [Related]
12. Bruton's tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice.
Kawata K; Hatano S; Baba A; Imabayashi K; Baba Y
Front Immunol; 2024; 15():1388947. PubMed ID: 38638439
[TBL] [Abstract][Full Text] [Related]
13. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
Front Immunol; 2018; 9():2027. PubMed ID: 30237801
[TBL] [Abstract][Full Text] [Related]
14. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
[TBL] [Abstract][Full Text] [Related]
15. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
16. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.
Barf T; Covey T; Izumi R; van de Kar B; Gulrajani M; van Lith B; van Hoek M; de Zwart E; Mittag D; Demont D; Verkaik S; Krantz F; Pearson PG; Ulrich R; Kaptein A
J Pharmacol Exp Ther; 2017 Nov; 363(2):240-252. PubMed ID: 28882879
[TBL] [Abstract][Full Text] [Related]
17. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
Ping L; Ding N; Shi Y; Feng L; Li J; Liu Y; Lin Y; Shi C; Wang X; Pan Z; Song Y; Zhu J
Oncotarget; 2017 Jun; 8(24):39218-39229. PubMed ID: 28424405
[TBL] [Abstract][Full Text] [Related]
18. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
da Cunha-Bang C; Niemann CU
Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
20. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
